Kimia Biosciences responded to a BSE query regarding significant price movement in its scrip on April 13, 2026.
The company confirmed compliance with SEBI LODR Regulation 30 and timely disclosure of all material events.
It clarified no undisclosed price sensitive information or pending corporate actions were affecting the share price.
Attributed the share price movement solely to market-driven factors outside the company's control.